Evidence map›Paper›PMID 38800607›Full record

ArticleAggregate (Hoboken, N.J.)2024

Gelatin methacryloyl granular scaffolds for localized mRNA delivery.

Bruna Gregatti Carvalho, Aya Nakayama, Hiromi Miwa, Sang Won Han, Lucimara Gaziola de la Torre, Dino Di Carlo, Junmin Lee, Han-Jun Kim, Ali Khademhosseini, Natan Roberto de Barros

Abstract read
In one paragraph

Article in Aggregate (Hoboken, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Unlock the sustained therapeutic efficacy of mRNA.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Review
  6. Article
  7. Growing Gold Nanostars on 3D Hydrogel Surfaces.Chemistry of materials : a publication of the American Chemical Society · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bruna Gregatti CarvalhoDepartment of Material and Bioprocess Engineering, School of Chemical Engineering, University of Campinas (UNICAMP), 13083-970, Brazil; Terasaki Institute for Biomedical Innovation (TIBI), 90064, USA.
Aya NakayamaTerasaki Institute for Biomedical Innovation (TIBI), 90064, USA.
Hiromi MiwaDepartment of Bioengineering, University of California at Los Angeles (UCLA), 90095, USA.
Sang Won HanCenter for Cell Therapy and Molecular, Federal University of São Paulo (UNIFESP), 04044-010, Brazil.
Lucimara Gaziola de la TorreDepartment of Material and Bioprocess Engineering, School of Chemical Engineering, University of Campinas (UNICAMP), 13083-970, Brazil.
Dino Di CarloDepartment of Bioengineering, University of California at Los Angeles (UCLA), 90095, USA.
Junmin LeeDepartment of Materials Science and Engineering, Pohang University of Science and Technology (POSTECH), 37673, Republic of Korea; Institute for Convergence Research and Education in Advanced Technology, Yonsei University, Incheon 21983, Republic of Korea.
Han-Jun KimTerasaki Institute for Biomedical Innovation (TIBI), 90064, USA; College of Pharmacy, Korea University, 30019, Republic of Korea; Vellore Institute of Technology (VIT), Vellore, 632014, India.
Ali KhademhosseiniTerasaki Institute for Biomedical Innovation (TIBI), 90064, USA.
Natan Roberto de BarrosTerasaki Institute for Biomedical Innovation (TIBI), 90064, USA.

Funding

Drug eluting injectable biomaterials for next generation chemoembolizationR01CA257558 · NCI · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2021 to 2025
$3.2M
Hemorrhage control in the irreversible anticoagulated patientR01HL137193 · NHLBI · MAYO CLINIC ARIZONA · PI OKLU, RAHMI · 2017 to 2021
$3.0M
Treatment of arterial aneurysms using an injectable biomaterialR01HL140951 · NHLBI · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2018 to 2021
$2.6M
Healing enterocutaneous fistulas using bioengineered biomaterialsR01DK130566 · NIDDK · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2022 to 2025
$2.2M
NCI NIH HHS R01 CA257558NHLBI NIH HHS R01 HL137193NHLBI NIH HHS R01 HL140951NIDDK NIH HHS R01 DK130566
6 · The paper itself

Abstract

mRNA therapy is the intracellular delivery of messenger RNA (mRNA) to produce desired therapeutic proteins. Developing strategies for local mRNA delivery is still required where direct intra-articular injections are inappropriate for targeting a specific tissue. The mRNA delivery efficiency depends on protecting nucleic acids against nuclease-mediated degradation and safe site-specific intracellular delivery. Herein, we report novel mRNA-releasing matrices based on RGD-moiety-rich gelatin methacryloyl (GelMA) microporous annealed particle (MAP) scaffolds. GelMA concentration in aerogel-based microgels (μgels) produced through a microfluidic process, MAP stiffnesses, and microporosity are crucial parameters for cell adhesion, spreading, and proliferation. After being loaded with mRNA complexes, MAP scaffolds composed of 10 % GelMA μgels display excellent cell viability with increasing cell infiltration, adhesion, proliferation, and gene transfer. The intracellular delivery is achieved by the sustained release of mRNA complexes from MAP scaffolds and cell adhesion on mRNA-releasing scaffolds. These findings highlight that hybrid systems can achieve efficient protein expression by delivering mRNA complexes, making them promising mRNA-releasing biomaterials for tissue engineering.

Indexed as

GelMAlipid-based nanocarriersMAP scaffoldsmicrofluidicsmRNA

Identifiers

PMID38800607
PMCPMC11126212

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.